Abstract
Background: About half of all prostate cancers harbor the TMPRSS2:ERG (T2E) gene fusion. While T2E-positive and T2E-negative tumors represent specific molecular subtypes of prostate cancer (PCa), previous studies have not yet comprehensively investigated how these tumor subtypes differ at the epigenetic level. We therefore investigated epigenome-wide DNA methylation profiles of PCa stratified by T2E status.
Results: The study included 496 patients with clinically localized PCa who had a radical prostatectomy as primary treatment for PCa. Fluorescence in situ hybridization (FISH) "break-apart" assays were used to determine tumor T2E- fusion status, which showed that 266 patients (53.6 %) had T2E-positive PCa. The study showed global DNA methylation differences between tumor subtypes. A large number of differentially methylated CpG sites were identified (false-discovery rate [FDR] Q-value
Conclusions: This study identified substantial differences in DNA methylation profiles of T2E-positive and T2E-negative tumors, thereby providing further evidence that different underlying oncogenic pathways characterize these molecular subtypes.
Original language | English |
---|---|
Article number | 128 |
Number of pages | 12 |
Journal | Clinical epigenetics |
Volume | 7 |
DOIs | |
Publication status | Published - 12 Dec 2015 |
Keywords
- DNA methylation
- CpG site
- Epigenetics
- Epigenomic profiling
- Prostate cancer
- Gene fusion
- TMPRSS2
- ERG
- Tumor tissue
- Unsupervised clustering
- mRNA expression
- C3orf14
- CACNA1D
- GREM1
- KLK10
- NT5C
- PDE4D
- RAB40C
- SEPT9
- TRIB2
- TCGA
- IN-SITU HYBRIDIZATION
- DNA METHYLATION
- BODY METHYLATION
- ERG-EXPRESSION
- ST ARRAYS
- ASSOCIATION
- TARGET
- TISSUE
- HYPERMETHYLATION
- REARRANGEMENTS